124 related articles for article (PubMed ID: 15638990)
1. Stability of Ala 125 recombinant human interleukin-2 in solution.
Reyes N; Ruiz L; Aroche K; Gerónimo H; Brito O; Hardy E
J Pharm Pharmacol; 2005 Jan; 57(1):31-7. PubMed ID: 15638990
[TBL] [Abstract][Full Text] [Related]
2. Development of a lyophilized formulation of interleukin-2.
Hora MS; Rana RK; Wilcox CL; Katre NV; Hirtzer P; Wolfe SN; Thomson JW
Dev Biol Stand; 1992; 74():295-303; discussion 303-6. PubMed ID: 1592178
[TBL] [Abstract][Full Text] [Related]
3. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design.
Vandecruys R; Peeters J; Verreck G; Brewster ME
Int J Pharm; 2007 Sep; 342(1-2):168-75. PubMed ID: 17573214
[TBL] [Abstract][Full Text] [Related]
4. Parameters for the evaluation of IL-2 stability.
Kenney WC; Watson E; Bartley T; Boone T; Altrock BW
Lymphokine Res; 1986; 5 Suppl 1():S23-7. PubMed ID: 3491260
[TBL] [Abstract][Full Text] [Related]
5. Development of a lyophilization formulation that preserves the biological activity of the platelet-inducing cytokine interleukin-11 at low concentrations.
Page C; Dawson P; Woollacott D; Thorpe R; Mire-Sluis A
J Pharm Pharmacol; 2000 Jan; 52(1):19-26. PubMed ID: 10716599
[TBL] [Abstract][Full Text] [Related]
6. Chemical conjugation of a novel antibody-interleukin 2 immunoconjugate against c-erbB-2 product.
Li J; Lee SE; Belciug M; Ring DB; Kwok CS
Chin Med J (Engl); 2000 Feb; 113(2):151-3. PubMed ID: 11775541
[TBL] [Abstract][Full Text] [Related]
7. Influence of packaging material on the liquid stability of interferon-alpha2b.
Ruiz L; Reyes N; Aroche K; Tolosa V; Simanca V; Rogríguez T; Hardy E
J Pharm Pharm Sci; 2005 Aug; 8(2):207-16. PubMed ID: 16124932
[TBL] [Abstract][Full Text] [Related]
8. [Studies on fermentation conditions and purification of mutant human interleukin-2 expressed in Pichia pastoris].
Liu Y; Su C; Hu YH; Ouyang KQ; Cai SX
Sheng Wu Gong Cheng Xue Bao; 2005 May; 21(3):430-4. PubMed ID: 16108369
[TBL] [Abstract][Full Text] [Related]
9. pH dependent effect of glycosylation on protein stability.
Wang W; Antonsen K; Wang YJ; Wang DQ
Eur J Pharm Sci; 2008 Feb; 33(2):120-7. PubMed ID: 18162379
[TBL] [Abstract][Full Text] [Related]
10. Stability of bortezomib 1-mg/mL solution in plastic syringe and glass vial.
André P; Cisternino S; Chiadmi F; Toledano A; Schlatter J; Fain O; Fontan JE
Ann Pharmacother; 2005 Sep; 39(9):1462-6. PubMed ID: 15985470
[TBL] [Abstract][Full Text] [Related]
11. The formulation of recombinant factor IX: stability, robustness, and convenience.
Bush L; Webb C; Bartlett L; Burnett B
Semin Hematol; 1998 Apr; 35(2 Suppl 2):18-21. PubMed ID: 9565162
[TBL] [Abstract][Full Text] [Related]
12. [Synergistic role between rhIL-2 and adriamycin long circulating temperature-sensitive liposome in targeting therapy on tumor].
Dong LF; Mei HS; Song SX; Lu ZJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 May; 21(3):296-300. PubMed ID: 15862144
[TBL] [Abstract][Full Text] [Related]
13. Characterization and aerodynamic evaluation of spray dried recombinant human growth hormone using protein stabilizing agents.
Jalalipour M; Gilani K; Tajerzadeh H; Najafabadi AR; Barghi M
Int J Pharm; 2008 Mar; 352(1-2):209-16. PubMed ID: 18164150
[TBL] [Abstract][Full Text] [Related]
14. Isolation and characterization of modified species of a mutated (Cys125 -Ala) recombinant human interleukin-2.
Moya G; González LJ; Huerta V; García Y; Morera V; Pérez D; Breña F; Araña M
J Chromatogr A; 2002 Sep; 971(1-2):129-42. PubMed ID: 12350108
[TBL] [Abstract][Full Text] [Related]
15. Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study.
Sosabowski JK; Lee M; Dekker BA; Simmons BP; Singh S; Beresford H; Hagan SA; McKenzie AJ; Mather SJ; Watson SA
Eur J Pharm Sci; 2007 Jun; 31(2):102-11. PubMed ID: 17387005
[TBL] [Abstract][Full Text] [Related]
16. Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin.
Nie Y; Zhang X; Wang X; Chen J
Bioconjug Chem; 2006; 17(4):995-9. PubMed ID: 16848407
[TBL] [Abstract][Full Text] [Related]
17. Screening for stability and compatibility conditions of recombinant human epidermal growth factor for parenteral formulation: effect of pH, buffers, and excipients.
Santana H; González Y; Campana PT; Noda J; Amarantes O; Itri R; Beldarraín A; Páez R
Int J Pharm; 2013 Aug; 452(1-2):52-62. PubMed ID: 23624083
[TBL] [Abstract][Full Text] [Related]
18. Dual effects of Tween 80 on protein stability.
Wang W; Wang YJ; Wang DQ
Int J Pharm; 2008 Jan; 347(1-2):31-8. PubMed ID: 17692480
[TBL] [Abstract][Full Text] [Related]
19. Long-term stabilization of recombinant human interferon alpha 2b in aqueous solution without serum albumin.
Ruiz L; Reyes N; Duany L; Franco A; Aroche K; Hardy Rando E
Int J Pharm; 2003 Oct; 264(1-2):57-72. PubMed ID: 12972336
[TBL] [Abstract][Full Text] [Related]
20. Oxidation of methionine residues in recombinant human interleukin-1 receptor antagonist: implications of conformational stability on protein oxidation kinetics.
Thirumangalathu R; Krishnan S; Bondarenko P; Speed-Ricci M; Randolph TW; Carpenter JF; Brems DN
Biochemistry; 2007 May; 46(21):6213-24. PubMed ID: 17480058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
